G1 Therapeutics Inc. said on Monday it would terminate a late-stage study of its lead drug as it was unlikely to be effective in extending survival in patients with a type of colorectal cancer, sending its shares plunging more than 50%.

The FDA has set a Feb. 9 meeting for its Oncologic Drugs Advisory Committee (ODAC) to discuss whether GSK’s clinical development plans for Jemperli (dostarlimab) could support accelerated approval.

Takeda entered into an exclusive licensing agreement with Hutchmed Limited to develop its colorectal cancer candidate, fruquintinib, beyond mainland China, Hong Kong and Macau.

The buyout will grant Leap Therapeutics access to Flame Bioscience’s portfolio, which includes a clinical-stage monoclonal antibody that is under investigation as a potential treatment for gastric, gastroesophageal junction, and pancreatic cancers.

In addition to becoming a Nasdaq-listed company, the focus of Elicio moving forward will be a therapeutic cancer vaccine candidate that targets mKRAS-driven tumors.

California-based Erasca announced Thursday it is expanding its existing partnership with Pfizer to assess ERAS-007 in combination with Pfizer’s Ibrance (palbociclib).

The European Commission is set to propose boosting regular screenings for cancer and expanding them to additional types of tumors, after check-ups fell dramatically during the COVID-19 pandemic, EU officials said on Wednesday.

Merck’s Keytruda (pembrolizumab) has taken another hit after the drug failed to meet dual primary endpoints in the Phase III KEYNOTE-921 trial for metastatic castration-resistant prostate cancer (mCRPC).

A study published this month in Science discusses data that may support a devious alter ego of T-cells present within colorectal cancer tumors.

Shares of Regulus Therapeutics plunged nearly 10% Monday after the company disclosed that its partner Sanofi has terminated a development agreement for a small RNA molecule inhibitor being developed for Alport syndrome. And on Monday, pharma giant Merck announced it has halted the Phase III LYNK-003 trial evaluating PARP inhibitor Lynparza for patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction.